PFIZER has signed a letter of intent with German firm BioNTech to collaborate on the co-development of a potential first-in-class COVID-19 vaccine.
The deal aims to accelerate development of BioNTech's mRNA-based vaccine candidate BNT162, with multiple R&D sites from both companies in the US and Germany set to commence work immediately on the project.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Mar 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 20
